• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

    1/10/25 8:05:00 AM ET
    $NXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXTC alert in real time by email

    BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced the first patient has been dosed in its Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC) as a therapeutic for treating multiple cancers.

    "Dosing the first patient in the LNCB74 Phase 1 study is a significant milestone for NextCure as we continue to advance our B7-H4 ADC program," said Udayan Guha, M.D., Ph.D., NextCure's Senior Vice President, Clinical & Translational Development. "We look forward to establishing the safety, tolerability, and preliminary anti-tumor activity of LNCB74. We believe this novel ADC could potentially transform treatment options for multiple cancers."

    In December 2024, NextCure announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for LNCB74.

    LNCB74 is being developed in partnership with LigaChem Biosciences, Inc. as part of a collaboration and co-development agreement.  

    About NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. www.nextcure.com

    Forward-Looking Statements

    Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to funding for our operations, objectives and expectations for our business, operations and financial performance and condition, including the progress and results of clinical trials, development plans and upcoming milestones regarding our therapies. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "continue," "could," "should," "due," "estimate," "expect," "intend," "hope," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "target," "towards," "forward," "later," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.

    Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and not having any products approved for commercial sale; NextCure's history of significant losses; NextCure's need and ability to obtain additional financing on acceptable terms or at all; risks related to clinical development, marketing approval and commercialization; and NextCure's dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described under the heading "Risk Factors" in NextCure's most recent Annual Report on Form 10-K and in NextCure's other filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

    Investor Inquiries

    Timothy Mayer, Ph.D.

    NextCure, Inc.

    Chief Operating Officer

    (240) 762-6486

    [email protected]



    Primary Logo

    Get the next $NXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXTC

    DatePrice TargetRatingAnalyst
    11/4/2022Buy → Neutral
    Ladenburg Thalmann
    3/1/2022$16.00Buy
    Ladenburg Thalmann
    11/5/2021$30.00 → $14.00Buy
    Needham
    More analyst ratings

    $NXTC
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by NextCure Inc.

      SCHEDULE 13G - NextCure, Inc. (0001661059) (Subject)

      5/12/25 12:54:33 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by NextCure Inc.

      10-Q - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:25:27 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NextCure, Inc. (0001661059) (Filer)

      5/1/25 4:15:24 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • NextCure downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded NextCure from Buy to Neutral

      11/4/22 1:03:13 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on NextCure with a new price target

      Ladenburg Thalmann initiated coverage of NextCure with a rating of Buy and set a new price target of $16.00

      3/1/22 7:18:07 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on NextCure with a new price target

      Needham reiterated coverage of NextCure with a rating of Buy and set a new price target of $14.00 from $30.00 previously

      11/5/21 8:42:25 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/14/24 6:59:21 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NextCure Inc.

      SC 13G/A - NextCure, Inc. (0001661059) (Subject)

      11/13/24 4:06:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by NextCure Inc.

      SC 13G - NextCure, Inc. (0001661059) (Subject)

      6/27/24 4:47:26 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

      Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported first quarter 2025 financial results. "With our LNCB74 antibody-drug conjugate ("ADC") program completing coho

      5/1/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

      BELTSVILLE, Md., April 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, at 8:45 am ET. A live audio webcast will be available through the Investors section of the company's website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative m

      4/4/25 7:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Full Year 2024 Financial Results

      Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025Cash of approximately $68.6 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., March 06, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported full year 2024 financial results. "In 2024 we reprioritized our resources to advance our antibody-drug conjugate ("ADC") program and recently completed cohor

      3/6/25 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Financials

    Live finance-specific insights

    See more
    • NextCure to Host Virtual Oncology Pipeline Update Event on November 15, 2021

      BELTSVILLE, Md., Nov. 01, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will host a Virtual Oncology Pipeline Update Event at 4:30 p.m. ET on Monday, November 15, 2021. During the event, NextCure will provide an update on its oncology pipeline, including data presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The event will also feature Roy Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Directo

      11/1/21 8:00:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

      BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4. "We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug c

      4/4/24 7:05:00 AM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board

      BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Lisa M. Coussens, PhD, FAACR, to its Scientific Advisory Board. As an accomplished translational tumor immunologist whose research is focused on the role immune cells play in tumor development, Dr. Coussens will support NextCure in its efforts to build and develop its proprietary pipeline of immunomedicines. "We are delighted to have Dr. Coussens join our Scientific Advisory Board, where she will leverage

      10/27/22 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

      BELTSVILLE, Md., March 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported fourth quarter and full year 2020 financial results and provided a business update. “Our team has worked diligently throughout 2020 to advance our programs despite the difficult environment created by the COVID-19 pandemic. We are thrilled that Dr. Han Myint has recently joined NextCure as our Chief Medical Officer and we are poised to harness his expertise in oncology product development to further advance our product pipe

      3/4/21 4:05:00 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NXTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Guha Udayan

      3 - NextCure, Inc. (0001661059) (Issuer)

      2/6/25 4:16:36 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sr VP, General Counsel Shaw Kevin G.

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:23:04 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Mayer Timothy

      4 - NextCure, Inc. (0001661059) (Issuer)

      2/3/25 6:22:50 PM ET
      $NXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care